Pages that link to "Q88065306"
Jump to navigation
Jump to search
The following pages link to Fred Saad (Q88065306):
Displaying 50 items.
- Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer (Q21136183) (← links)
- Abiraterone in metastatic prostate cancer without previous chemotherapy (Q24612084) (← links)
- The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements (Q26750672) (← links)
- Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy (Q26786543) (← links)
- Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline (Q26852544) (← links)
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials (Q28275006) (← links)
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (Q28275476) (← links)
- Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay (Q28546630) (← links)
- Abiraterone and increased survival in metastatic prostate cancer (Q29617512) (← links)
- Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer (Q29994552) (← links)
- Psychosocial Adjustment of Men During the First Year of Prostate Cancer (Q30226478) (← links)
- Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference (Q30438167) (← links)
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial (Q33434260) (← links)
- The aging male population and medical care for benign prostatic hyperplasia in Canada (Q33754025) (← links)
- Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options (Q33754036) (← links)
- Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience (Q33843663) (← links)
- Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer (Q33978286) (← links)
- eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression (Q34069836) (← links)
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma (Q34152748) (← links)
- Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer (Q34335996) (← links)
- Guidelines for the management of castrate-resistant prostate cancer (Q34384240) (← links)
- Enzalutamide in metastatic prostate cancer before chemotherapy (Q34422206) (← links)
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer (Q34570396) (← links)
- The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence (Q34602179) (← links)
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer (Q34898980) (← links)
- The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate (Q35004491) (← links)
- Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer (Q35022212) (← links)
- Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. (Q35063446) (← links)
- Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid (Q35065540) (← links)
- Radiation-induced hemorrhagic cystitis (Q35203193) (← links)
- Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th (Q35549709) (← links)
- Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer (Q35569309) (← links)
- Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. (Q35583788) (← links)
- Role of bisphosphonates in prostate cancer (Q35604838) (← links)
- Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective (Q35605711) (← links)
- Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology (Q35673265) (← links)
- Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone (Q35717793) (← links)
- Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review (Q35774987) (← links)
- Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada (Q35781093) (← links)
- The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion. (Q35795265) (← links)
- Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid (Q35865726) (← links)
- Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care (Q35952799) (← links)
- The role of bisphosphonates in the management of bone metastases in prostate cancer. (Q35970139) (← links)
- The role of bisphosphonates in hormone-refractory prostate cancer (Q36017885) (← links)
- UPM3: review of a new molecular diagnostic urine test for prostate cancer. (Q36075821) (← links)
- Bone loss in prostate cancer: evaluation, treatment and prevention. (Q36075851) (← links)
- Early detection of prostate cancer with ultrasound-guided systematic needle biopsy (Q36194137) (← links)
- Bone health in men with prostate cancer: diagnostic and therapeutic considerations. (Q36194142) (← links)
- Low-risk prostate cancer patient: active treatment (Q36194146) (← links)
- Sarcopenia during androgen-deprivation therapy for prostate cancer (Q36212442) (← links)